乳腺癌辅助内分泌治疗概况  

Adjuvant endocrine therapy for breast cancer

作　　者：刘风华[1] 张璐[1] 张晶倩[1] 

机构地区：[1]中国中医科学院广安门医院外科,北京100053

出　　处：《国际外科学杂志》2008年第1期54-56,共3页International Journal of Surgery

摘　　要：乳腺癌的内分泌治疗是激素依赖型乳腺癌患者重要的辅助治疗之一，分为手术治疗和非手术治疗，近年来手术及放射去势治疗逐渐被药物治疗替代。雌激素受体和／或孕激素受体阳性，是目前临床应用内分泌治疗的重要指标。绝经前后患者内分泌环境的生理差别决定了用药方式的不同。绝经前患者主要抑制卵巢产生雌激素，而绝经后患者主要抑制芳香化酶的功能。本文旨在对乳腺癌患者内分泌常用药物进行简要介绍，并就他莫西芬及芳香化酶抑制剂进行重点介绍。The endocrine therapy is one of the most important adjuvant therapies for patients with hormone-dependent breast cancer. It is divided into surgical and non-surgical therapy treatment, surgical treatment and radiotherapy were gradually replaced by drug treatment. Estrogen receptor and （or） progesterone receptor positive are important indicator of receiving endocrine therapy in the current clinical therapy. The physiological difference of endocrine environment between patients before and after menopause determines medication. Pre-menopausal patients ovarian were inhibited to produce estrogen, but postmenopausal patients aromatase function were inhibited mainly. The article is to introduce the endocrine drugs for breast cancer patients and focus on tamoxifen and focus on aromatase inhibitors.

关 键 词：乳腺癌 内分泌治疗 他莫昔芬 芳香化酶抑制剂 

分 类 号：R737.9[医药卫生—肿瘤]